Comparative Efficacy of Lebrikizumab, Dupilumab, and Tralokinumab in Maintaining Treatment Response in Atopic Dermatitis at Varying Treatment Continuance Rates. J of Skin 2025, 9 (1), s519. https://doi.org/10.25251/skin.9.supp.519.